Doug Williams - British Amer Executive Vice-President Chief Business Officer
| BTI Stock | CAD 0.01 1.24 99.60% |
President
Mr. Doug Williams, MBA., is Executive VicePresident, Chief Business Officer of the Company. Williams has more than 20 years of experience in the pharmaceutical and healthcare industries and has successfully led crossfunctional, global alliances teams across multiple organizations. His alliance and partnering experience includes a broad set of partners including large, multinational pharmaceutical companies, as well as startup biotechnology companies, which included global alliances with Shionogi, Exicure, AbbVie, Mylan and Takeda, among others. Williams was recognized as an industry leader who has presented, participated as a panelist, and moderated multiple industry partnering programs at industry events. Williams most recently came from Purdue Pharma L.P where he worked on strategic alliances and business development projects related to clinical and preclinical programs. Prior to Purdue, Williams built his own successful consulting business working with startup healthcare technology companies. Doug experience includes commercial sales, sales management, alliance management and business development. He has also held various positions of increasing responsibility at Pfizer, Johnson Johnson, Elan, Sepracor and Kadmon over his 20 year career. since 2017.
| Tenure | 7 years |
| Professional Marks | MBA |
| Address | 157 Church Street, New Haven, CT, United States, 06510 |
| Phone | 203 533 7082 |
| Web | https://www.bioasis.us |
British Amer Management Efficiency
The company has return on total asset (ROA) of (0.8058) % which means that it has lost $0.8058 on every $100 spent on assets. This is way below average. British Amer's management efficiency ratios could be used to measure how well British Amer manages its routine affairs as well as how well it operates its assets and liabilities. At this time, British Amer's Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 1.54 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (6.59). At this time, British Amer's Non Current Assets Total are fairly stable compared to the past year. Intangible Assets is likely to climb to about 452.7 K in 2024, whereas Total Current Assets are likely to drop slightly above 711.9 K in 2024.Similar Executives
| Found 7 records | PRESIDENT Age | ||
| Aron Levine | Bank of America | N/A | |
| James DeMare | Bank of America | 54 | |
| Dean Athanasia | Bank of America | 57 | |
| Jeneen Marziani | Bank of America | N/A | |
| Matthew Koder | Bank of America | 52 | |
| Daniel Pinto | JPMorgan Chase Co | 61 | |
| Paul Douglas | Toronto Dominion Bank | 67 | |
Management Performance
| Return On Asset | -0.81 |
biOasis Technologies Leadership Team
Elected by the shareholders, the British Amer's board of directors comprises two types of representatives: British Amer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of British. The board's role is to monitor British Amer's management team and ensure that shareholders' interests are well served. British Amer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, British Amer's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Wurzer, Independent Director | ||
| Doug Williams, Executive Vice-President Chief Business Officer | ||
| David Jenkins, Chief Officer | ||
| Mario Saltarelli, Non-Executive Director | ||
| Graeme Dick, Director Relations | ||
| Doug MBA, Exec Officer | ||
| Christine Antalik, Chief Financial Officer | ||
| John Curran, Independent Director | ||
| Kim Elton, Director Marketing | ||
| Caroline Dircks, Chief Operating Officer | ||
| Deborah Rathjen, Executive Chairman of the Board, President, Chief Executive Officer | ||
| Aaron Elton, Director Marketing | ||
| Mei Tian, VP Research | ||
| Dave Jenkins, Chief Officer | ||
| B FTSE, CEO Chairman |
British Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is British Amer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.81 | ||||
| Operating Margin | (4.69) % | ||||
| Current Valuation | 2.45 M | ||||
| Shares Outstanding | 79.41 M | ||||
| Shares Owned By Insiders | 2.05 % | ||||
| Number Of Shares Shorted | 105.04 K | ||||
| Price To Earning | 25.91 X | ||||
| Price To Book | 54.04 X | ||||
| Price To Sales | 1.47 X | ||||
| Revenue | 269.38 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for British Stock Analysis
When running British Amer's price analysis, check to measure British Amer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy British Amer is operating at the current time. Most of British Amer's value examination focuses on studying past and present price action to predict the probability of British Amer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move British Amer's price. Additionally, you may evaluate how the addition of British Amer to your portfolios can decrease your overall portfolio volatility.